Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease Hiroaki Hayashi, MD, Chihiro.

Slides:

Advertisements

Similar presentations

A bioinformatics approach to identify patients with symptomatic peanut allergy using peptide microarray immunoassay Jing Lin, PhD, Francesca M. Bruni,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor κB activation So Ri Kim, MD, PhD, Dong Im Kim, MS, Mi.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Von Ta, MD, Andrew A. White, MD

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Katharine M. Woessner, MD, FAAAAI, Andrew A. White, MD, FAAAAI

Fatty acids, inflammation, and asthma

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Ann-Marie M. Schoos, MD, PhD, Jacob D

Aspirin-induced urticaria and angioedema, but not bronchoconstriction, associated with cysteinyl leukotriene overproduction in 2 patients with asthma

Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis Yuma Fukutomi, MD,

Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2.

Is 9 more than 2 also in allergic airway inflammation?

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers Noritaka Higashi, MD, PhD, Haruhisa Mita, PhD,

Association between (CCTTT)n repeat polymorphism in NOS2 promoter and asthma exacerbations Keita Hirai, PhD, Toshihiro Shirai, MD, PhD, Masayuki Suzuki,

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Katherine N. Cahill, MD, Jillian C. Bensko, Joshua A

CD203c expression on human basophils is associated with asthma exacerbation Emiko Ono, MD, PhD, Masami Taniguchi, MD, PhD, Noritaka Higashi, MD, PhD,

Physician needs in health informatics: Just ask the docs

Treatment of chronic autoimmune urticaria with omalizumab

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction Silvia Carraro, MD, Massimo Corradi,

William J. Calhoun, MD, Tmirah Haselkorn, PhD, Dave P

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature Jessica P. Rajan, MD, Nathan E. Wineinger,

Smoking Cessation as a Possible Risk Factor for the Development of Aspirin- Exacerbated Respiratory Disease in Smokers Hiroaki Hayashi, MD, Yuma Fukutomi,

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Repeated Episodes of Anaphylaxis with Normal Serum Tryptase but Elevated Levels of Urinary Prostaglandin D2 Phillip Lieberman, MD The Journal of Allergy.

Reply Journal of Allergy and Clinical Immunology

Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Ovalbumin content of influenza vaccines

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think Martin L. Moore, PhD, R.

CC chemokine receptors CCR1 and CCR4 are expressed on airway mast cells in allergic asthma Kawa Amin, PhD, Christer Janson, MD, PhD, Ilkka Harvima, MD,

Effect of ingested H1 antihistamines on methacholine challenge

What is an “eosinophilic phenotype” of asthma?

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Higher incidence of pediatric anaphylaxis in northern areas of the United States William J. Sheehan, MD, Dionne Graham, PhD, Lin Ma, MS, Sachin Baxi,

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis Grazyna Bochenek, MD, PhD, Joanna Kuschill-Dziurda,

One step forward, 2 steps back: The enigma of preschool wheeze

Von Ta, MD, Andrew A. White, MD

Jessica H. Savage, MD, MHS, Elizabeth C. Matsui, MD, MHS, Robert A

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Macrolide antibiotics and asthma treatment

Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin- induced asthma Yukio Kawagishi, MDa,b, Haruhisa Mita, PhDb, Masami Taniguchi,

Asthma: The past, future, environment, and costs

Environmental factors and eosinophilic esophagitis

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease Chihiro Mitsui, MD, Keiichi Kajiwara, BSc, Emiko Ono, MD, PhD,

Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years Malgorzata Setkowicz, MD, PhD, Lucyna Mastalerz,

Urinary tetranor-PGDM concentrations in aspirin-intolerant asthma and anaphylaxis Noritaka Higashi, MD, PhD, Haruhisa Mita, PhD, Hiromichi Yamaguchi,

Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma Naomi Tsurikisawa, MD, Hiroshi Saito,

Presentation transcript:

Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease Hiroaki Hayashi, MD, Chihiro Mitsui, MD, Eiji Nakatani, MS, Yuma Fukutomi, MD, PhD, Keiichi Kajiwara, BSc, Kentaro Watai, MD, Kiyoshi Sekiya, MD, Takahiro Tsuburai, MD, PhD, Kazuo Akiyama, MD, Yoshinori Hasegawa, MD, PhD, Masami Taniguchi, MD, PhD Journal of Allergy and Clinical Immunology Volume 137, Issue 5, Pages 1585-1587.e4 (May 2016) DOI: 10.1016/j.jaci.2015.09.034 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Urinary concentrations of LTE4 and PGD2M before and after omalizumab treatment in responders and nonresponders. Data on PGDE2M concentrations are missing from 8 patients. Urinary LTE4 and PGD2M concentrations are expressed using a log scale. Horizontal bars indicate median values. Journal of Allergy and Clinical Immunology 2016 137, 1585-1587.e4DOI: (10.1016/j.jaci.2015.09.034) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig E1 Physicians' Global Evaluations of Treatment Effectiveness (GETE) at study end. GETE was used to assess control of asthma symptoms in response to the omalizumab treatment, as excellent (complete control), good (marked improvement), moderate (discernible, but limited improvement), poor (no appreciable change), or worsening. Patients with an “excellent” or “good” response were classified as responders, whereas those with a “moderate,” “poor,” or “worsening” response were classified as nonresponders.E1-E3 Journal of Allergy and Clinical Immunology 2016 137, 1585-1587.e4DOI: (10.1016/j.jaci.2015.09.034) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions